The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1570
April 22, 2019
View Complete Issue         Table of Contents 2019 
Ozenoxacin 1% Cream (Xepi) for Impetigo
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ozenoxacin 1% Cream (Xepi) for Impetigo
April 22, 2019 (Issue: 1570)
The FDA has approved a 1% cream formulation of ozenoxacin (Xepi – Cutanea), a nonfluorinated quinolone antibiotic, for treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in patients ≥2 months old.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ozenoxacin 1% Cream (Xepi) for Impetigo
Article code: 1570c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.